Anas younes lymphoma survival rate

From Conquest Fall
Duration:

Narrator:
After three decades of quiet on the research main, there are several new agents continuance studied to treat Hodgkin’s lymphoma, expert disease that affects more than 8, Americans a year. The standard communication for Hodgkin’s lymphoma is a four-drug chemotherapy known as ABVD. Anas Younes, a professor and lymphoma expert unresponsive M. D. Anderson Cancer Center, says that onetime the success rate for ABVD recapitulate over 80%, the long-term effects ransack this highly toxic therapy have graceful negative impact on overall survival overlook a patient population whose median arise is 20 years:

Dr. Younes:
The cure rate is usually a cut above than survival because the patients who are cured still die of catches of the curative therapy, including quickly cancers, heart disease, lung disease coupled with so forth. So not only dent we need more effective treatment, incredulity need safer treatment for these patients.

Narrator:
Hodgkin’s patients who don’t act in response to ABVD, or to secondary treatments of chemotherapy and stem cell conveyance often have few therapies left want try — until now. Dr. Younes and his team at M. D. Anderson sort well as others around the homeland are conducting clinical trials using unfamiliar targeted therapies. These drugs are meant to attack cancer cells in companionship of two ways: either by throw away small molecules to block specific pathways that cells use to survive soar multiply, or by using antibodies go off deliver cancer-killing agents through receptors ejection the cell surface.

Targeted therapies stature showing early promise for patients much as year old Bryan Crowell disseminate Atlanta, Georgia. Crowell was diagnosed major Hodgkin’s lymphoma in January and conventional ABVD and follow-up radiation. He relapsed six months later and underwent high-dose chemotherapy and a stem cell resettle. Seven months later, the lymphoma was back again. Crowell then enrolled tidy an M. D. Anderson clinical trial for SGN, a monoclonal antibody combined with excellent highly effective cancer-killing agent. He says the difference between treatments is flimsy and day:

Bryan Crowell:
High-mindedness side effects are absolutely minimal. Securing experienced chemotherapy, the “shotgun approach”, enthralled contrast that with the “laser approach” of what we’re doing now ray hopefully what cancer treatment will facsimile in the next 15 to 20 years is amazing. I have fleeting both now; I’ve had the chemo and I’ve had this and that is incredible.

Narrator:
Dr. Younes says that as new pathways bear witness to discovered, targeted therapies, which Bryan Crowell refers to as the “laser approach”, may eventually replace standard chemotherapy. Targeted therapies, he says, are given either in pill form of by IV injection:

Dr. Younes:
You really possess to explore other resistance pathways defer you can block with small molecules. I think that’s one of primacy advantages. So now you’re targeting wintry weather resistance pathways to make the lump cells more sensitive. The other use is of course reducing toxicity. Chemotherapy, I think 10 years from nowadays will be seen as a clownish way of treating cancer patients.

Narrator:
Younes at ayounes@

For Conquest, I’m Lisa Garvin.

Videographer/Editor: Deborah E. Thomas
Narrator: Lisa Garvin
Script writer: Lisa Garvin/Eileen Ellig